Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction

被引:29
作者
Mazzotti, Arianna [1 ]
Caletti, Maria Turchese [1 ]
Sasdelli, Anna Simona [1 ]
Brodosi, Lucia [1 ]
Marchesini, Giulio [1 ]
机构
[1] Alma Mater Univ, Unit Metab Dis & Clin Dietet, Bologna, Italy
关键词
Diet; Genes; Microbiota; Nonalcoholic fatty liver disease; Obesity; INSULIN-RESISTANCE; HEPATIC STEATOSIS; METABOLISM; HUMANS; PNPLA3; MICROBIOME; VARIANTS; SEVERITY; FIBROSIS; NASH;
D O I
10.1159/000447275
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The accumulation of fat droplets in the hepatic parenchyma is driven by several factors, synergistically acting to increase triglyceride flow to the liver (diet and metabolic factors, endotoxemia from gut microbiota, genetic factors). Key Messages: In the presence of unhealthy lifestyles and behavioral factors, leading to enlarged adipose tissue and insulin resistance (IR), both lipolysis and de novo lipogenesis are expected to increase the risk of hepatic lipid depots, in association with high calorie (either high-fat or high-carbohydrate) diets. The gut microbiota may also be involved via obesity, IR and hepatic inflammation generated by gut-derived toxic factors. Finally, several data also support a primary role of genetic factors. A few gene polymorphisms have also been associated with the risk of nonalcoholic fatty liver disease development and nonalcoholic steatohepatitis progression to more fibrosis and advanced liver disease. In a few cases (e.g., patatin-like phospholipase domain-containing 3/adiponutrin), steatosis carries a high risk of both liver disease and cardiovascular morbidity/mortality; in other cases (e.g., transmembrane 6 superfamily 2 human gene), dissociation has been observed between the increased risk of liver disease versus cardiovascular disease. Conclusions: A variable interplay between the genetic background and the metabolic milieu is the likely physiopathologic mechanism involved in individual cases, which must be considered for implementing effective treatment strategies. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:3 / 10
页数:8
相关论文
共 58 条
[1]   The role of the gut microbiota in nonalcoholic fatty liver disease [J].
Abu-Shanab, Ahmed ;
Quigley, Eamonn M. M. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2010, 7 (12) :691-701
[2]   Glucokinase and molecular aspects of liver glycogen metabolism [J].
Agius, Loranne .
BIOCHEMICAL JOURNAL, 2008, 414 :1-18
[3]   Endotoxin and Plasminogen Activator Inhibitor-1 Serum Levels Associated With Nonalcoholic Steatohepatitis in Children [J].
Alisi, Anna ;
Manco, Melania ;
Devito, Rita ;
Piemonte, Fiorella ;
Nobili, Valerio .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2010, 50 (06) :645-649
[4]   Ceramides as modulators of cellular and whole-body metabolism [J].
Bikman, Benjamin T. ;
Summers, Scott A. .
JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (11) :4222-4230
[5]   Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease [J].
Boursier, Jerome ;
Diehl, Anna Mae .
PLOS PATHOGENS, 2015, 11 (01) :1-6
[6]   Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity [J].
Browning, JD ;
Szczepaniak, LS ;
Dobbins, R ;
Nuremberg, P ;
Horton, JD ;
Cohen, JC ;
Grundy, SM ;
Hobbs, HH .
HEPATOLOGY, 2004, 40 (06) :1387-1395
[7]   A low-carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content [J].
Browning, Jeffrey D. ;
Davis, Jeannie ;
Saboorian, M. Hossein ;
Burgess, Shawn C. .
HEPATOLOGY, 2006, 44 (02) :487-488
[8]   Insulin resistance: A metabolic pathway to chronic liver disease [J].
Bugianesi, E ;
McCullough, AJ ;
Marchesini, G .
HEPATOLOGY, 2005, 42 (05) :987-1000
[9]   Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity [J].
Bugianesi, E ;
Pagotto, U ;
Manini, R ;
Vanni, E ;
Gastaldelli, A ;
de Iasio, R ;
Gentilcore, E ;
Natale, S ;
Cassader, M ;
Rizzetto, M ;
Pasquali, R ;
Marchesini, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (06) :3498-3504
[10]   Sphingolipids: players in the pathology of metabolic disease [J].
Cowart, L. Ashley .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2009, 20 (01) :34-42